BDNF in inflammation and neuropathologies

BDNF in inflammation and neuropathologies

BDNF Overview

Brain-derived neurotrophic factor (BDNF) is a central mediator of neuroplasticity, a term used to describe the ability of neurons to adapt in response to challenges, resulting in structural and functional changes to neurons (Huang et al, 2001). BDNF is the second member of the neurotrophin family to be identified, with nerve growth factor (NGF) discovered 3 decades prior (Barde et al, 1982; Levi-Montalcini and Hamburger, 1951). Several other neurotrophic factors have since been discovered, all possessing distinct functions in specified areas of the central nervous system (CNS) (Shen et al, 1997). BDNF is expressed throughout the CNS, although particularly high BDNF expression is found in the hippocampus and cerebral cortex, and is primarily expressed in neurons (Murrer et al, 1999; Conner et al, 1997).

The Role of BDNF in Neuroplasticity

Many studies have identified neurotrophins as critical modulators of neurogenesis (Zigova et al, 1998). BDNF specifically regulates axon and dendrite growth, receptor trafficking to the membrane, and the release of neurotransmitters, enabling synaptic transmission (Pease et al, 2000; Gottschalk et al, 1998; Segal et al, 1995). Multiple studies have demonstrated the essential role of BDNF in long term potentiation (LTP), with a fluctuation in BDNF levels during learning (Kesslak et al, 1998), and knockout studies showing increased cognitive impairment (Minichiello et al, 1999).

BDNF Signalling

Structurally, BDNF is a homodimer and is composed of signal peptide sequence, and an N-glycosylation site. It is located in the nerve terminals and transported throughout the neuron in an anterograde fashion (Altar et al, 1997). Cleavage of BDNF must occur in order to assume its active role (Chao and Bothwell, 2002). Secreted BDNF binds to the tyrosine kinase receptor tropomyosin-related kinase B, also known as tyrosine-kinase B (trkB). Ligation of trkB induces its autophosphorylation and allows subsequent interactions between trkB and multiple cytoplasmic adaptor proteins, such as phospholipase C (PLC-g), culminating in the activation of MAPK and cyclic AMP-response element binding protein (CREB) pathways downstream (Patapoutian and Reichardt, 2001). Several studies have shown that BDNF can interact with a truncated from of trkB (Fryer et al, 1997), and it has been proposed that this binding activates a form of negative regulation of full-length trkB by sequestering BDNF (Haapasalo et al, 2001; Eide et al, 1996), although more recent studies have suggested that truncated trkB may also initiate signalling through RhoGTPases and Ca2+ -dependent pathways (Fenner et al, 2012; Rose et al, 2003).

The Role of BDNF in Mediating Inflammatory Signalling

BDNF signalling can modulate key pro-inflammatory transcription factors, such as NF-kB and AP-1, and limit the inflammatory response (Xu et al, 2017). Interestingly, pro-inflammatory cytokine stimulation downregulates BDNF expression in the hippocampus and cerebral cortex of mice (Guan and Fang, 2006; Lapchak et al, 1993), demonstrating bi-directional communication between BDNF and immune signalling, and also highlighting the impact of inflammatory pathogenesis on neuronal homeostasis. Additionally, there is evidence that glucocorticoids reduce BDNF, further linking the inflammatory response to neurotrophin levels (Gubba et al, 2004).

The Role of BDNF in Neuropathologies

BDNF is downregulated in response to acute and chronic stress and chronic inflammation(Jiang et al, 2011; Shi et al, 2010), and altered BDNF levels are also associated with the pathogenesis of depression (Zhang et al, 2014; Shimizu et al, 2003). Moreover, absence of the truncated form of trkB resulted in a delayed onset of Amyotrophic Lateral Sclerosis in mice (Yanpellewar et al, 2012). Additionally, reduced levels of BDNF are reported in schizophrenia (Chen da et al, 2009), and specifically in the hippocampi of Alzheimer’s disease (Burbach et al, 2004) and Parkinson’s disease pathogeneses (Howells et al, 2000). Elevated levels of BDNF are evident in epileptogenesis, with the inhibition of trkB, using anti-trkB antibodies resulting in reduced pathogenesis (Binder et al, 2009). However, BDNF has been demonstrated to exert anti-inflammatory and anti-apoptotic effects by downregulating NF-kB and AP-1 signal transduction in a bacterial meningitis model of disease, indicating the complexity of BDNF and the duality of its role which is apparently stimulus and disease specific (Xu et al, 2017). Another study demonstrated in a stroke model that BDNF exerts similar anti-inflammatory effects by upregulating IL-10 and downregulating TNFa, as a protective anti-inflammatory mechanism (Jiang et al, 2010). Increased metastasis has been described in neuroblastoma in a BDNF-MAPK dependent manner, highlighting the need to tightly control BDNF signalling in order to combat tumourigenesis (Hua et al, 2016). With the therapeutic potential of BDNF growing more attractive, small molecule BDNF mimics have been developed and have been successful in attenuating the pathology of traumatic brain injury (Wurzelmann et al, 2017). Increases in BDNF using molecular mimics to treat Alzheimer’s disease has also been explored (Leyhe et al, 2008). These exciting results have given a strong basis for the potential future success of BDNF modulation for the treatment of neurological disorders.

Figure 1: BDNF signalling. BDNF binds to the tyrosine kinase receptor B (trkB) initiating receptor autophosphorylation and the activation of the trkB kinase activity. Downstream binding to acitvators of MAPK, Akt, Ca2+ and CREB pathways leads to increases in neurogenesis, long-term potentiation and synaptic plasticity, as well as downregulation of immune signalling pathways via the transcription factors NF-kB and AP-1.

References

  1. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson AL, Lindsay RM, Wiegand SJ. Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature. 1997. 389(6653):856-60.
  2. Barde YA, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982. 1(5):549-53.
  3. Binder DK, Routbort MJ, Ryan TE, Yancopoulos GD, McNamara JO. Selective inhibition of kindling development by intraventricular administration of TrkB receptor body. J Neurosci. 1999. 19(4):1424-36.
  4. Burbach GJ, Hellweg R, Haas CA, Del Turco D, Deicke U, Abramowski D, Jucker M, Staufenbiel M, Deller T. Induction of brain-derived neurotrophic factor in plaque-associated glial cells of aged APP23 transgenic mice. J Neurosci. 2004. 24(10):2421-30.
  5. Calabrese F, Rossetti AC, Racagni G, Gass P, Riva MA, Molteni R. Brain derived neurotrophic factor: a bridge between inflammation and neuroplasticity. Front Cell Neurosci. 2014. 22;8:430.
  6. Chao MV, Bothwell M. Neurotrophins: to cleave or not to cleave. Neuron. 2002. 33(1):9-12.
  7. Chen da C, Wang J, Wang B, Yang SC, Zhang CX, Zheng YL, et al. Decreased levels of serum brain-derived neurotrophic factor in drug-naive first-episode schizophrenia: relationship to clinical phenotypes. Psychopharmacology (Berl). 2009. 207;375-380.
  8. Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci. 1997. 17(7):2295-313.
  9. Eide FF, Vining ER, Eide BL, Zang K, Wang XY, Reichardt LF. Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci. 1996. 16(10):3123-9.
  10. Fenner BM. Truncated TrkB: beyond a dominant negative receptor. Cytokine Growth Factor Rev. 2012. 23(1-2):15-24.
  11. Fryer RH, Kaplan DR, Kromer LF. Truncated trkB receptors on non-neuronal cells inhibit BDNF-induced neurite outgrowth in vitro. Exp Neurol. 1997. 148(2):616-27.
  12. Gottschalk W, Pozzo-Miller LD, Figurov A, Lu B. Presynaptic modulation of synaptic transmission and plasticity by brain-derived neurotrophic factor in the developing hippocampus. J Neurosci. 1998. 18(17):6830-9.
  13. Guan, Z., and Fang, J. Peripheral immune activation by lipopolysaccharide decreases neurotrophins in the cortex and hippocampus in rats. Brain Behav. Immun. 2006. 20, 64–71.
  14. Gubba, E. M., Fawcett, J. W., and Herbert, J. The effects of corticosterone and dehydroepiandrosterone on neurotrophic factor mRNA expression in primary hippocampal and astrocyte cultures. Brain Res. Mol. Brain Res. 2004. 127, 48–59.
  15. Haapasalo A, Koponen E, Hoppe E, Wong G, Castrén E. Truncated trkB.T1 is dominant negative inhibitor of trkB.TK+-mediated cell survival. Biochem Biophys Res Commun. 2001. 280(5):1352-8.
  16. Howells DW, Porritt MJ, Wong JY, Batchelor PE, Kalnins R, Hughes AJ, Donnan GA. Reduced BDNF mRNA expression in the Parkinson’s disease substantia nigra. Exp Neurol. 2000. 166(1):127-35.
  17. Hua Z, Gu X, Dong Y, Tan F, Liu Z, Thiele CJ, Li Z. PI3K and MAPK pathways mediate the BDNF/TrkB-increased metastasis in neuroblastoma. Tumour Biol. 2016. 37, 12:16227-16236.
  18. Huang, E. J., and Reichardt, L. F. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 2001. 24, 677–736.
  19. Jiang Y, Wei N, Zhu J, Lu T, Chen Z, Xu G, Liu X. Effects of brain-derived neurotrophic factor on local inflammation in experimental stroke of rat. Mediators Inflamm. 2010. 2010:372423.
  20. Kesslak JP, So V, Choi J, Cotman CW, Gomez-Pinilla F. Learning upregulates brain-derived neurotrophic factor messenger ribonucleic acid: a mechanism to facilitate encoding and circuit maintenance? Behav Neurosci. 1998. 112(4):1012-9.
  21. Lapchak, P. A., Araujo, D. M., and Hefti, F. Systemic interleukin-1 beta decreases brain-derived neurotrophic factor messenger RNA expression in the rat hippocampal formation. Neuroscience. 2003. 53, 297–301.
  22. Levi-Montalcini R, Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool. 1951. 116(2):321-61.
  23. Leyhe T, Stransky E, Eschweiler GW, Buchkremer G, Laske C. Increase of BDNF serum concentration during donepezil treatment of patients with early Alzheimer’s disease. Eur Arch Psychiatry Clin Neurosci. 2008. 258(2):124–128.
  24. Lu, B., Pang, P. T., and Woo, N. H. The yin and yang of neurotrophin action. Nat. Rev. Neurosci. 2005. 6, 603–614.
  25. Minichiello L, Korte M, Wolfer D, Kühn R, Unsicker K, Cestari V, Rossi-Arnaud C, Lipp HP, Bonhoeffer T, Klein R. Essential role for TrkB receptors in hippocampus-mediated learning. Neuron. 1999. 24(2):401-14.
  26. Murer MG, Boissiere F, Yan Q, Hunot S, Villares J, Faucheux B, Agid Y, Hirsch E, Raisman-Vozari R. An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer’s disease. Neuroscience. 1999. 88(4):1015-32.
  27. Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol. 2001. 11(3):272-80.
  28. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci. 2000. 41(3):764-74.
  29. Rose CR, Blum R, Pichler B, Lepier A, Kafitz KW, Konnerth A. Truncated TrkB-T1 mediates neurotrophin-evoked calcium signalling in glia cells. Nature. 2003. 426(6962):74-8.
  30. Segal RA, Pomeroy SL, Stiles CD. Axonal growth and fasciculation linked to differential expression of BDNF and NT3 receptors in developing cerebellar granule cells. J Neurosci. 1995. 15(7 Pt 1):4970-81.
  31. Shen L, Figurov A, Lu B. Recent progress in studies of neurotrophic factors and their clinical implications. J Mol Med (Berl). 1997. 75(9):637-44.
  32. Shi SS, Shao SH, Yuan BP, Pan F, Li ZL. Acute stress and chronic stress change brain-derived neurotrophic factor (BDNF) and tyrosine kinase-coupled receptor (TrkB) expression in both young and aged rat hippocampus. Yonsei Med J. 2010. 51(5):661-71.
  33. Shimizu, E. et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003. 54, 70–75,
  34. Wurzelmann M, Romeika J, Sun D. Therapeutic potential of brain-derived neurotrophic factor (BDNF) and a small molecular mimics of BDNF for traumatic brain injury. Neural Regen Res. 2017. 12(1):7-12.
  35. Xu D, Lian D, Wu J, Liu Y, Zhu M, Sun J, He D, Li L. Brain-derived neurotrophic factor reduces inflammation and hippocampal apoptosis in experimental Streptococcus pneumoniae meningitis. J Neuroinflammation. 2017. 14(1):156.
  36. Yanpallewar SU, Barrick CA, Buckley H, Becker J, Tessarollo L. Deletion of the BDNF truncated receptor TrkB.T1 delays disease onset in a mouse model of amyotrophic lateral sclerosis. PLoS One. 2012. 7(6):e39946.
  37. Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K. Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol. 2014. 18(4).
  38. Zigova T, Pencea V, Wiegand SJ, Luskin MB. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol Cell Neurosci. 1998. 11(4):234-45.
18th May 2020 Sinéad Kinsella PhD

Recent Posts